Professor Hisham Mehanna

InHANSE, Institute of Cancer and Genomic Sciences, University of Birmingham

Professor Mehanna is the Chair of Head and Neck Surgery, and Director of InHANSE, at the University of Birmingham.

Hisham’s clinical interests are recurrence head and neck cancer surgery and thyroid and minimal access parathyroid surgery.

Hisham has a keen interest in clinical and translational research, heading a research team of 20 researchers, and holding over £10million in research grants. The main areas of his research are Human Papillomavirus-associated head and neck cancer and thyroid cancer. His research themes are drug development and redeployment, biomarkers of treatment response and early and late phase clinical trials in head and neck cancer. He is chief investigator of several multicentre and multinational clinical trials, including the PET NECK trial, published in the NEJM in 2016.

He is currently President of the British Association of Head Neck Oncologists (BAHNO) and past Chair of the Research Committee of BAHNO, the UK’s multi-disciplinary professional body, and past Chair of the UK’s National Cancer Research Institute’s head and neck group, responsible for all head neck cancer research in the UK.

dont miss

Clinical trials that change patient care and the lessons learnt

We will give examples of studies in head and neck cancer that have changed patient care, and the lessons learnt in running these studies.

EVEN MORE SEMINARS

  • Dr Keith Tsui: Speaking at the Oncology Convention

    Dr Keith Tsui
    Medopad

    Remote Patient Monitoring: Bringing the Hospital into the Home

  • Hamed Javan MD: Speaking at the Oncology Convention

    Hamed Javan MD
    Jewish General Hospital

    Systemic Cancer Therapy: Pancreatic and Colorectal Cancer – Pre-operative FOLFIRINOX in pancreatic cancer

  • Dr Nathan Hill & Dr James Watson: Speaking at the Oncology Convention

    Dr Nathan Hill & Dr James Watson
    MedInfomatics Ltd

    Electronic Medical Records – have they lived up to expectations?

  • Khurum Khan: Speaking at the Oncology Convention

    Khurum Khan
    Royal Marsden NHS Foundation Trust

    Biomarkers of response and/or resistance to targeted therapies in refractory mCRC

  • Professor Hisham Mehanna: Speaking at the Oncology Convention

    Professor Hisham Mehanna
    InHANSE, Institute of Cancer and Genomic Sciences, University of Birmingham

    Clinical trials that change patient care and the lessons learnt